嗜酸性粒细胞疾病的新型疗法。
Novel Therapies for Eosinophilic Disorders.
作者信息
Bochner Bruce S
机构信息
Division of Allergy-Immunology, Department of Medicine, Northwestern University Feinberg School of Medicine, 240 East Huron Street, Room M-306, Chicago, IL 60611, USA.
出版信息
Immunol Allergy Clin North Am. 2015 Aug;35(3):577-98. doi: 10.1016/j.iac.2015.05.007.
Abstract
Current therapies for eosinophilic disorders are limited. Most treatment approaches remain empirical, are not supported by data from controlled clinical trials, involve the off-label use of agents developed for treatment of other diseases, and tend to rely heavily on the use of glucocorticoids and other agents with significant toxicity. Great progress has been made in the discovery, preclinical development, and clinical testing of a variety of biologics and small molecules that have the potential to directly or indirectly influence eosinophils, eosinophilic inflammation, and the consequences of eosinophil activation.
摘要
目前针对嗜酸性粒细胞疾病的治疗方法有限。大多数治疗方法仍属经验性，缺乏对照临床试验数据的支持，涉及使用为治疗其他疾病而研发药物的超说明书用药，并且往往严重依赖糖皮质激素及其他具有显著毒性的药物。在发现、临床前开发和临床试验各种有可能直接或间接影响嗜酸性粒细胞、嗜酸性粒细胞炎症以及嗜酸性粒细胞活化后果的生物制剂和小分子方面，已经取得了巨大进展。
相似文献
1
Novel Therapies for Eosinophilic Disorders.
Immunol Allergy Clin North Am. 2015 Aug;35(3):577-98. doi: 10.1016/j.iac.2015.05.007.
2
Mepolizumab in eosinophilic disorders.
Expert Rev Clin Immunol. 2011 Jul;7(4):411-7. doi: 10.1586/eci.11.27.
3
Anti-interleukin-5 antibody therapy in eosinophilic diseases.
Pathobiology. 2005;72(6):287-92. doi: 10.1159/000091326.
4
Targeted Anti-IL-5 Therapies and Future Therapeutics for Hypereosinophilic Syndrome and Rare Eosinophilic Conditions.
Clin Rev Allergy Immunol. 2020 Oct;59(2):231-247. doi: 10.1007/s12016-019-08775-4.
5
Treatment of hypereosinophilic syndrome and eosinophilic dermatitis with reslizumab.
Ann Allergy Asthma Immunol. 2018 Jun;120(6):670-671. doi: 10.1016/j.anai.2018.02.017. Epub 2018 Feb 26.
6
Eosinophilic disorders in children.
Curr Allergy Asthma Rep. 2006 Nov;6(6):475-82. doi: 10.1007/s11882-006-0024-5.
7
Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes.
J Allergy Clin Immunol. 2004 Jan;113(1):115-9. doi: 10.1016/j.jaci.2003.10.049. Epub 2003 Dec 12.
8
A review of treatment with mepolizumab, an anti-IL-5 mAb, in hypereosinophilic syndromes and asthma.
J Allergy Clin Immunol. 2010 Apr;125(4):803-13. doi: 10.1016/j.jaci.2009.11.048.
9
Biological Modulators in Eosinophilic Diseases.
Clin Rev Allergy Immunol. 2016 Apr;50(2):252-72. doi: 10.1007/s12016-014-8444-9.
10
Hypereosinophilic syndrome and mepolizumab.
N Engl J Med. 2008 Jun 26;358(26):2838-9; author reply 2839-40. doi: 10.1056/NEJMc080856.
引用本文的文献
1
The Comparative Effectiveness of Mepolizumab and Benralizumab in the Treatment of Eosinophilic Asthma.
Adv Respir Med. 2025 Jun 20;93(4):21. doi: 10.3390/arm93040021.
2
Current and emerging biologic therapies targeting eosinophilic disorders.
World Allergy Organ J. 2022 Jul 31;15(8):100676. doi: 10.1016/j.waojou.2022.100676. eCollection 2022 Aug.
3
The Association between a Decrease in On-Treatment Neutrophil-to-Eosinophil Ratio (NER) at Week 6 after Ipilimumab Plus Nivolumab Initiation and Improved Clinical Outcomes in Metastatic Renal Cell Carcinoma.
Cancers (Basel). 2022 Aug 7;14(15):3830. doi: 10.3390/cancers14153830.
4
Role of Eosinophils in Intestinal Inflammation and Fibrosis in Inflammatory Bowel Disease: An Overlooked Villain?
Front Immunol. 2021 Oct 19;12:754413. doi: 10.3389/fimmu.2021.754413. eCollection 2021.
5
Emerging Evidence for Pleiotropism of Eosinophils.
Int J Mol Sci. 2021 Jun 30;22(13):7075. doi: 10.3390/ijms22137075.
6
Prediction of non-muscle-invasive bladder cancer recurrence during intravesical BCG immunotherapy by use of peripheral blood eosinophil count and percentage: a preliminary report.
Cancer Immunol Immunother. 2021 Jan;70(1):245-252. doi: 10.1007/s00262-020-02673-x. Epub 2020 Jul 22.
7
Contributions of Eosinophils to Human Health and Disease.
Annu Rev Pathol. 2020 Jan 24;15:179-209. doi: 10.1146/annurev-pathmechdis-012419-032756.
8
Revisiting the NIH Taskforce on the Research needs of Eosinophil-Associated Diseases (RE-TREAD).
J Leukoc Biol. 2018 Jul;104(1):69-83. doi: 10.1002/JLB.5MR0118-028R. Epub 2018 Apr 19.
9
The eosinophil: For better or worse, in sickness and in health.
Ann Allergy Asthma Immunol. 2018 Aug;121(2):150-155. doi: 10.1016/j.anai.2018.02.031. Epub 2018 Feb 27.
10
Eosinophils: The unsung heroes in cancer?
Oncoimmunology. 2017 Nov 13;7(2):e1393134. doi: 10.1080/2162402X.2017.1393134. eCollection 2018.
本文引用的文献
1
Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study.
Gut. 2015 Jun;64(6):894-900. doi: 10.1136/gutjnl-2014-308337. Epub 2015 Jan 7.
2
Determinants of eosinophil survival and apoptotic cell death.
Apoptosis. 2015 Feb;20(2):224-34. doi: 10.1007/s10495-014-1072-2.
3
A nonsteroidal glucocorticoid receptor agonist inhibits allergen-induced late asthmatic responses.
Am J Respir Crit Care Med. 2015 Jan 15;191(2):161-7. doi: 10.1164/rccm.201404-0623OC.
4
A randomized trial of benralizumab, an antiinterleukin 5 receptor α monoclonal antibody, after acute asthma.
Am J Emerg Med. 2015 Jan;33(1):14-20. doi: 10.1016/j.ajem.2014.09.036. Epub 2014 Oct 5.
5
Immunological profiling in chronic rhinosinusitis with nasal polyps reveals distinct VEGF and GM-CSF signatures during symptomatic exacerbations.
Clin Exp Allergy. 2015 Apr;45(4):767-78. doi: 10.1111/cea.12463.
6
Novel targeted therapies for eosinophil-associated diseases and allergy.
Annu Rev Pharmacol Toxicol. 2015;55:633-56. doi: 10.1146/annurev-pharmtox-010814-124407. Epub 2014 Oct 17.
7
Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study.
Lancet Respir Med. 2014 Nov;2(11):879-890. doi: 10.1016/S2213-2600(14)70201-2. Epub 2014 Oct 8.
8
Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study.
Gut. 2015 Feb;64(2):243-9. doi: 10.1136/gutjnl-2014-308004. Epub 2014 Oct 10.
9
Histologic eosinophilic gastritis is a systemic disorder associated with blood and extragastric eosinophilia, TH2 immunity, and a unique gastric transcriptome.
J Allergy Clin Immunol. 2014 Nov;134(5):1114-24. doi: 10.1016/j.jaci.2014.07.026. Epub 2014 Sep 15.
10
Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study.
Lancet Respir Med. 2014 Nov;2(11):891-901. doi: 10.1016/S2213-2600(14)70187-0. Epub 2014 Sep 7.
Zotero 插件